Combating Residual Risk with Treatment Intensification: Focus on PCSK9 Inhibitors – A Care Team Forum℠

Program Overview

This activity features an engaging video panel discussion with 3 renowned clinical experts and Charles—a patient living with familial hypercholesterolemia (FH). The lively exchange is enhanced with explanatory visuals; direct note-taking capability; interactive questions; and a full in-suit resource library. The panel will delve into topics covering safety/efficacy data for PCSK9 inhibitors (PCSK9-Is), 2018 ACC/AHA guideline updates, and patient selection for treatment intensification with PCSK9-Is. Faculty will examine key matters in patient care, provide illustrative patient case scenarios, pose practical solutions to common issues encountered in clinical practice, and Charles will provide insight into his experience with FH, its treatment, and his interaction with the healthcare system.

Credit Expired
CE Credit Expired
Expires: May 14, 2020

Target Audience

The target audience for this activity is lipidologists, endocrinologists, cardiologists, internal medicine and family medicine physicians, NPs, and PAs who manage patients with hypercholesterolemia.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Use PCSK9 inhibitors to manage hypercholesterolemia based on patient characteristics, guidelines, MOA, and efficacy and safety data

Activity Faculty



Clinical Assistant Professor, Medicine
NYU School of Medicine and NYU Center for CV Prevention
Director, Bellevue Hospital Lipid Clinic
New York, NY


Christie M. Ballantyne, MD

Professor and Vice Chair, Research
Department of Medicine
Director, Center for Cardiometabolic Prevention
Chief, Sections of Cardiology and Cardiovascular Research
Baylor College of Medicine
Houston, TX


Gregory P. Hess, MD, MBA, MSc

Instructor, Department of Emergency Medicine
Drexel University College of Medicine
Adjunct Senior Fellow, Leonard Davis Institute for Health Economics
University of Pennsylvania
Philadelphia, PA

Supporter Statement

Provider Statement

Disclosure of Financial Relationships


Planners and Managers

Method of Participation and Request for Credit

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Copyright Statement

© Copyright 2024. All rights reserved. Developed and managed by RMEI Medical Education, LLC. Laurel Office Plaza | 101 Laurel Road, Suite 200 | Voorhees, NJ 08043 | | (866) 770-RMEI


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources